Compare Stocks → You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CARANASDAQ:PEPGNASDAQ:VAXXNASDAQ:VRCA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$0.69-5.5%$0.82$0.50▼$4.67$37.72M0.7667,695 shs363,035 shsPEPGPepGen$11.85+3.0%$13.86$3.72▼$17.51$372.08M1.5451,780 shs47,171 shsVAXXVaxxinity$0.46+12.1%$0.68$0.39▼$3.10$52.98M2.39303,735 shs435,167 shsVRCAVerrica Pharmaceuticals$6.90-2.3%$5.67$2.86▼$7.76$299.48M1.88172,796 shs202,527 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics-5.72%-14.88%-22.47%+22.12%-83.57%PEPGPepGen+3.00%-6.81%-15.21%+76.00%-5.32%VAXXVaxxinity+11.20%-11.97%-36.76%-35.29%-77.55%VRCAVerrica Pharmaceuticals-2.27%-2.40%+45.57%+16.75%+9.35%New crypto project uncovers 2,050% in 65 days (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics3.9034 of 5 stars3.42.00.04.22.01.71.3PEPGPepGen2.143 of 5 stars3.53.00.00.01.32.50.6VAXXVaxxinity1.1706 of 5 stars3.50.00.00.00.63.30.6VRCAVerrica Pharmaceuticals3.4982 of 5 stars3.51.00.04.70.62.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics2.75Moderate Buy$9.751,313.04% UpsidePEPGPepGen3.00Buy$24.67108.25% UpsideVAXXVaxxinity3.00Buy$7.001,406.02% UpsideVRCAVerrica Pharmaceuticals3.00Buy$11.2563.04% UpsideCurrent Analyst RatingsLatest VRCA, VAXX, CARA, and PEPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/10/2024VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/28/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/7/2024PEPGPepGenWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.003/6/2024CARACara TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/5/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/1/2024VRCAVerrica PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.003/1/2024VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.001/30/2024PEPGPepGenWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$21.001/22/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $5.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$20.97M1.80N/AN/A$1.05 per share0.66PEPGPepGenN/AN/AN/AN/A$4.55 per shareN/AVAXXVaxxinity$70K841.62N/AN/A$0.11 per share4.23VRCAVerrica Pharmaceuticals$5.12M57.17N/AN/A$0.47 per share14.68Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$2.18N/AN/AN/A-565.21%-122.10%-89.64%5/20/2024 (Estimated)PEPGPepGen-$78.63M-$3.31N/AN/AN/AN/A-57.56%-45.55%5/9/2024 (Estimated)VAXXVaxxinity-$56.93M-$0.45N/AN/AN/AN/A-192.58%-88.04%5/14/2024 (Estimated)VRCAVerrica Pharmaceuticals-$67M-$1.46N/AN/AN/A-1,307.47%-119.46%-70.35%5/14/2024 (Estimated)Latest VRCA, VAXX, CARA, and PEPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023VAXXVaxxinity-$0.13-$0.09+$0.04-$0.09N/AN/A3/6/2024Q4 2023PEPGPepGen-$1.01-$0.82+$0.19-$0.82N/AN/A3/4/202412/31/2023CARACara Therapeutics-$0.57-$0.59-$0.02-$0.59$2.34 million$3.00 million 2/29/2024Q4 2023VRCAVerrica Pharmaceuticals-$0.47-$0.48-$0.01-$0.43$1.10 million$1.99 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/AVAXXVaxxinityN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.544.43PEPGPepGenN/A6.436.43VAXXVaxxinity0.991.891.89VRCAVerrica Pharmaceuticals2.224.554.49OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%PEPGPepGen58.01%VAXXVaxxinity82.95%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics4.20%PEPGPepGen3.97%VAXXVaxxinity59.07%VRCAVerrica Pharmaceuticals41.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics5554.66 million52.36 millionOptionablePEPGPepGen6432.35 million31.07 millionNot OptionableVAXXVaxxinity57126.75 million51.88 millionNot OptionableVRCAVerrica Pharmaceuticals10042.42 million24.82 millionOptionableVRCA, VAXX, CARA, and PEPG HeadlinesSourceHeadlineVerrica Pharmaceuticals (NASDAQ:VRCA) Given "Buy" Rating at Needham & Company LLCamericanbankingnews.com - April 11 at 5:14 AMNeedham & Company LLC Reiterates "Buy" Rating for Verrica Pharmaceuticals (NASDAQ:VRCA)marketbeat.com - April 10 at 8:24 AMVerrica Pharmaceuticals to Spotlight Innovations at Needham Healthcare Conferencemsn.com - April 4 at 11:15 AMStrong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year lossfinance.yahoo.com - April 3 at 8:23 AMVerrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 2 at 7:30 AMVerrica Pharmaceuticals Secures Key FDA Designation for YCANTH, Enhancing Market Protectionmsn.com - March 31 at 11:37 AMVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDAfinanznachrichten.de - March 28 at 3:45 PMVerrica Pharma gains as FDA lists Ycanth in Orange Bookmsn.com - March 27 at 3:42 AMVerrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick Factsmarkets.businessinsider.com - March 26 at 8:15 AMVerrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDAglobenewswire.com - March 26 at 7:30 AMVerrica Pharmaceuticals Set to Illuminate TD Cowen Healthcare Conference with Fireside Chatmsn.com - March 3 at 10:22 PMVerrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - March 2 at 10:39 AMWhen Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?finance.yahoo.com - March 2 at 10:39 AMVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Resultsfinanznachrichten.de - March 1 at 11:46 PMVerrica Pharmaceuticals Outperforms with YCANTH Sales, Promising Outlook Spurs Buy Ratingmarkets.businessinsider.com - March 1 at 6:46 PMBuy Rating Affirmed for Verrica Pharmaceuticals Following Strong Ycanth Launch and Strategic Market Expansionmarkets.businessinsider.com - March 1 at 6:46 PMVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 1 at 1:45 PMBuy Rating Affirmed for Verrica Pharmaceuticals Amidst Promising Ycanth Launch and Market Acceptancemarkets.businessinsider.com - February 29 at 10:09 PMVerrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Resultsfinance.yahoo.com - February 29 at 12:07 PMVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Resultsglobenewswire.com - February 29 at 7:30 AMEarnings Outlook For Verrica Pharmaceuticalsbenzinga.com - February 28 at 6:01 PMVerrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conferenceglobenewswire.com - February 27 at 7:30 AMVerrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024finance.yahoo.com - February 22 at 10:58 AMVerrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024globenewswire.com - February 22 at 7:30 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCara TherapeuticsNASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.PepGenNASDAQ:PEPGPepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.VaxxinityNASDAQ:VAXXVaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.Verrica PharmaceuticalsNASDAQ:VRCAVerrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.